A Two Part Phase IIa/b Multicentre Randomised Double-Blind Placebo-Controlled Parallel Group Dose-ranging Study to Assess Efficacy Safety and Tolerability of the Combination of Zibotentan and Dapagliflozin and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.